"While we estimate this FDA approval will only increase the approved population by 2 million, we see the potential for these studies to expand corporate insurance coverage by an incremental 40% given other medicines approved to treat this indication are typically covered," Goldman explained
Gustafsson H, Sderdahl T, Jnsson G, Bratteng JO, Forsby A
a , Scatter plot showing the relative fold change (log 2 ) in oxidized cysteine reactivity versus relative fold change (log 2 ) in protein expression from Slc33a1- knockout KPK cells expressing a vector control compared to SLC33A1 cDNA
What are its benefits
Healthcare providers can address underlying health factors that might affect treatment success while providing ongoing support and guidance throughout the process
Compounding from these substances is not permitted, and the agency is reviewing whether they should be added to the do-not-compound list